DENVER, Colo. – The International Association for the Study of Lung Cancer’s (IASLC) Strategic Screening Advisory Committee will hold the Third CT Screening Workshop on Saturday, Sept. 5 at 9 a.m. at the Colorado Convention Center, Rooms 708+710+712, prior to the official opening of the 16th Annual World Conference on Lung Cancer (WCLC). International leaders in computed tomography (CT) screening from across the world, including Japan, Australia, Canada, Europe and the U.S., are set to participate.
Speaking in an interview with Oncology Nursing News, Dr. Fred R. Hirsch, CEO of IASLC, Professor of Medicine and Pathology at the University of Colorado, discusses the importance of combination therapies in the fight against lung cancer.
IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer
One in every 10 cigarettes, and many other tobacco products, consumed worldwide are illegal, making the illicit trade of tobacco products a major global concern from many perspectives, including health, legal, economic, governance and corruption.
The study identifies a subset of patients with small cell lung cancer with potentially over activated FGFR1 pathways as evidenced by FGFR1 gene amplification, increased FGFR1 mRNA levels, and high protein expression.
Small cell lung cancer (SCLC) will be the concentrated focus when 100 global experts in the field meet for a workshop hosted by the International Association for the Study of Lung Cancer (IASLC) on April 22-24, 2015 at Memorial Sloan Kettering Cancer Center in New York City.